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Abstract
(±)-α-Vinyllysine and (±)-α-vinylarginine display time-dependent inhibition of L-lysine 
decarboxylase from B. cadaveris, and L-arginine decarboxylase from E. coli, respectively. A 
complete Kitz-Wilson analysis has been performed using a modification of the Palcic continuous 
UV assay for decarboxylase activity.
As part of a program directed at the synthesis of new, α-branched amino acids, we have 
previously described a convenient method for the synthesis of α-vinyl amino acids,1a,b and 
for their enzymatic resolution.1c We have also established that α-vinyl amino acids are 
useful precursors to the corresponding α-chlorovinyl,1d α-bromovinyl1d and α-oxiranyl 
amino acids.1e Herein, we provide a detailed kinetic characterization of two new time-
dependent inhibitors of the α-vinyl amino acid class.
Several α-vinyl amino acids are known to act as mechanism-based inhibitors for pyridoxal 
phosphate dependent enzymes. The simplest α-vinyl amino acid, α-vinylglycine, is a natural 
product2 and inactivates transaminases for L-aspartate, L-alanine, L-serine and D-
alanine.3a–e One decarboxylase, L-cysteine sulfinate decarboxylase, is also irreversibly 
inactivated by α-vinylglycine.3f Peptidylglycine α-hydroxylating monooxygenase (PHM) is 
irreversibly inhibited by a D-α-vinylglycine-containing tripeptide.4
The higher vinyl amino acids (with R groups,, more complex than hydrogen) are not known 
natural products, though a considerable number have been synthesized.1a,5 Previous work 
has shown that DOPA decarboxylase,6 ornithine decarboxylase7 and glutamate 
decarboxylase,8 all important medicinal targets, are irreversibly inhibited by the 
corresponding (±)-α-vinyl amino acids. In the cases of α-vinylhistidine6a and α-vinylserine9 
(reversible) competitive inhibition is observed with the PLP-dependent histidine 
decarboxylase and with serine hydroxymethyltransferase, respectively. A related vinyl 
amino acid, γ-vinyl-GABA (Vigabatrin) is a time-dependent inhibitor of GAB A 
transaminase and an anti-epileptic drug.10 Elegant studies by Silverman and coworkers have 
provided useful insights into the mechanism of action of this γ-vinyl-γ-amino acid.11
*This is necessary because there is always a small background rate due to exogenous CO2 in the control cuvet. For the assay cuvet, 
there is an additional, albeit small, component of the background rate due to residual α-vinyllysine decarboxylation, which must be 
subtracted out to obtain the true rate of lysine decarboxylation. Background rates were ≤10% of vo.
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Using our formal vinylation procedure,1a we synthesized (±)-α-vinylarginine (1) and (±)-α-
vinyllysine (2) as potential mechanism-based inhibitors of L-arginine decarboxylase (ADC) 
and L-lysine decarboxylase (LDC), respectively. Indeed, several other a-branched (primarily 
α-halogenomethyl) amines and amino acids have been developed by others as mechanism-
based inhibitors of ADC12 and LDC.13 These two amino acid decarboxylases are important 
targets for the development of antiproliferative agents as their reaction products feed into the 
polyamine pathway. The ADC reaction product, agmatine, is converted to putrescine via 
agmatine amidinohydrolase (agmatinase; EC 1.5.3.11). The LDC reaction product, 
cadaverine, is used as a putrescine-surrogate in a modified polyamine pathway found in 
tumor cells that have been exposed to ornithine DC inhibitors.14 ADC inhibitors are also 
potential antibiotics as this enzyme is found in bacterial and plants, but not in mammalian 
systems.12
Time-Dependent Inhibition Kinetics
We wished to use a continuous UV assay to evaluate (±)-α-vinylarginine and (±)-α-
vinyllysine for time-dependent inhibition of their cognate decarboxylases in contrast to the 
radioactive, time-point assay that has been traditionally used.6–8 We chose to develop a 
modified version of the assay described by Palcic and coworkers.15 In this assay, the CO2 
formed upon decarboxylation is trapped by phosphoenolpyruvate carboxylase (PEPC)-
mediated condensation with PEP to produce oxaloacetate. Subsequent in situ reduction of 
the oxaloacetate to L-malate with malate dehydrogenase results in a decrease in O.D.340 due 
to the oxidation of NADH to NAD+. Whereas Palcic used a CO2 kit for this assay, we chose 
to assemble each of the individual components, and in so doing, to optimize the assay in 
terms of pH and source and amount of each enzyme, in particular. Our optimal conditions 
are presented below. These assay conditions were first tested for each enzyme by carrying 
out a standard Lineweaver-Burk steady state kinetic analysis with the natural substrate. In 
this way, we obtained Km = 180 μM for L-arginine with arginine decarboxylase (Figure 1) 
and Km = 640 μM for L-lysine with lysine decarboxylase (Figure 2).
Optimized Continuous UV Assay for Decarboxylase Activity
General—The assay cuvet (total volume 1 mL) contained 80 mM potassium phosphate 
buffer (pH 6.8), 2 mM L-lysine, 0.4 mM PLP, 0.01 U lysine DC (Bacterium cadaveris, 55 
U/mg protein, single band on SDS-PAGE), 2 mM PEP, 10 mM MgCl2, 0.9 U PEPC (Zea 
mays), 0.04 U carbonic anhydrase, 1.5 U malate dehydrogenase, 0.21 mM NADH.
Time-dependent inhibition assays—Et cuvet: the enzyme was incubated with (±)-α-
vinyllysine and all other components with the exception of lysine. Eo cuvet: A control cuvet 
identical to the Et cuvet, but lacking inhibitor, was incubated under the same conditions. 
After incubation of both cuvets at 25° C for a time t, background rates for each cuvet were 
measured by monitoring ΔO.D.340 vs. time.* L-lysine (2 mM) was then added to each cuvet 
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and initial rates were measured as before. For primary plots, Et/Eo was calculated as follows: 
Et = vo[(LDC + I) + L-lys]t − vo(LDC + I)t and Eo = vo(LDC + L-lys)t−vo(LDC)t.
For arginine DC (E. Coli., 215 U/mg protein, single band on SDS-PAGE), the same 
procedure was followed except that all incubations and assays were run at pH 6.5.
Then, for each inhibitor and each enzyme, a complete Kitz-Wilson analysis16 was 
performed. This involves pre-incubating a given decarboxylase with a fixed concentration of 
its cognate α-vinyl amino acid inhibitor candidate (vide supra). The slope of the primary 
plot (ln(E/Eo) vs. time of incubation) corresponds to an apparent inactivation constant for 
that inhibitor concentration. After repeating the experiment at several inhibitor 
concentrations, a secondary plot {reciprocal kinact(apparent) versus 1/[} is constructed, the 
intercept and slope of which provide kinact and KI, respectively:
Primary Plot: ln(E/E0) = −[kinact/(1 + KI/[I])]t
Secondary Plot: −1/primary slope = 1/kinact(apparent) = (KI/kinact)(I/[I]) + 1/kinact
As can be seen from Figures 3–6 both (±)-α-vinylarginine and (±)-α-vinyllysine exhibit 
well-behaved time-dependent inhibition of their cognate DC’s. We obtain, KI = 1.8 mM and 
kinact = 3.6 × 10−2 min−1 for (±)-α-vinylarginine with L-arginine DC. These data indicate a 
relatively weak affinity of this enzyme for this α-branched alternative substrate, though the 
rate of inactivation is quite respectable. On the other hand, (±)-α-vinyllysine displays KI = 
0.5 mM and kinact = 2 × 102 min−1 with L-lysine DC. While the observed first order 
inactivation rate constant here is marginally smaller than that observed for (±)-α-
vinylarginine with arginine DC, the KI is respectable. If one considers that the enzyme 
probably turns over only one enantiomer (subject to future verification) of this apparent 
Trojan horse inhibitor, the KI is actually about 250 μM, which is nearly a factor of three 
smaller than Km. This indicates that an α-vinyl substituent is particularly well-tolerated by 
LDC. Furthermore, dialysis of inhibited LDC against several changes of buffer (conditions 
under which LDC activity does not decrease) fails to restore any LDC activity, indicating 
that the observed inhibition is irreversible.
Summary
Using our procedure for the formal α-vinylation of α-amino acids, (±)-α-vinylarginine and 
(±)-α-vinyllysine were synthesized. A modification of the continuous UV assay for 
decarboxylases reported by Palcic was used to conveniently perform a Kitz-Wilson kinetic 
analysis for time-dependent inhibition with these α-branched amino acids. Indeed, both 
compounds display pseudo-first order time-dependent inhibition of their respective amino 
acid decarboxylases, with (±)-α-vinyllysine displaying a KI that compares favorably with 
Km.
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
Berkowitz et al. Page 10
Bioorg Med Chem Lett. Author manuscript; available in PMC 2017 November 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
